Development of telomerase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 12, 2001, Pages 1815-1823

  Rowley, P T ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Antisense; Cancer; G quadruplex; Reverse transcriptase; Ribozyme; Telomerase; Telomeres

Indexed keywords

(PYRIDIN 3 YLCARBONYL)OXYMETHYL BUTYRATE; 2 (2 METHOXYETHOXY)ACETYLOXYMETHYL BUTYRATE; 2 [2 (2 METHOXYETHOXY)ETHOXY]ACETYLOXYMETHYL BUTYRATE; 2 [4 [4 CHLORO 6 (3 SULFOPHENYLAMINO) 1,3,5 TRIAZIN 2 YL AMINO]PHENYL] 6 METHYLBENZOTHIAZOLE; 3,4 DIMETHOXYCINNAMOYLOXYMETHYL BUTYRATE; 5,10,15,20 TETRAKIS(N METHYL 4 PYRIDYL)PORPHINE; [2 (1 AMINOETHYL)PYRIDINE] 2,3 DIBROMOSUCCINATE PLATINUM; [2 (2 AMINO ETHYL)PYRIDINE]HEMIMELLITATE PLATINUM; ALPHA METHYL 4 (2 ETHYLPROPYL)BENZENEACETYLOXYMETHYL BUTYRATE; ANTHRAQUINONE DERIVATIVE; ANTISENSE OLIGONUCLEOTIDE; BENZOTHIOPHENE DERIVATIVE; BUTYRYLOXYMETHYL DIETHYL PHOSPHATE; CATECHIN; DNA POLYMERASE; ESTER DERIVATIVE; GUANINE; IMIDE; ISATIN DERIVATIVE; N,N' BIS[2 (1 PIPERIDINO)ETHYL] 3,4,9,10 PERYLENETETRACARBOXYLIC DIIMIDE; PLATINUM COMPLEX; PORPHYRIN DERIVATIVE; RIBONUCLEOPROTEIN; RIBOZYME; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE; TELOMERASE INHIBITOR; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; CANCER CELL; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; CHROMOSOME; CONTROLLED STUDY; DNA BINDING; DNA SYNTHESIS; DRUG CLASSIFICATION; DRUG INHIBITION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; REVIEW; TELOMERE;

EID: 0035207750     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.12.1815     Document Type: Review

References (45)

1. Aging and cancer: Are telomeres and telomerase the connection?
2. Specific association of human telomerase activity with immortal cells and cancer
3. Telomerase in the early detection of cancer
4. Clinical implications of telomerase in cancer
5. Telomeres and aging: Fact, fancy, and the future
6. Telomere loss: Mitotic clock or genetic time bomb?
7. Extension of life-span by introduction of telomerase into normal human cells
8. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA
9. Inhibition of telomerase limits the growth of human cancer cells
10. Telomeric repeat from T. thermophila cross hybridizes with human telomeres
11. n, present at the telomeres of human chromosomes
12. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats
13. The remaking of chromosomes: The collecting net
14. The stability of broken ends of chromosomes in Zea mays
15. Human telomeres are attached to the nuclear matrix
16. Identification of a specific-telomere terminal transferase activity in Tetrahymena extracts
17. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity
18. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis
19. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP)
20. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity
21. Comparison of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit
22. Telomerase inhibitors
23. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
24. Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells
25. G-strings at chromosome ends
26. 3] G-tetraplex
27. G-quadruplex DNA: A target for drug design
28. G-quadruplexes as targets for drug design
29. Structure-activity relationships among guanine-quadruplex telomerase inhibitors
30. NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA
31. Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule
32. Telomere maintenance mechanisms as a target for drug development
33. Development of retinoblastoma in the absence of telomerase activity
34. Telomere elongation in immortal human cells without detectable telomerase activity
35. An alternative pathway for yeast telomere maintenance rescues est1-senesence
36. Transposons in place of telomeric repeats at a Drosophila telomere
37. Accurate determination of telomerase activity requires removal of inhibitors to PCR
38. Is telomerase a universal cancer target?
39. Structure and variability of human chromosome ends
40. Agents that target telomerase and telomeres
41. Telomerase targeting in cancer treatment: New developments
42. Preclinical and clinical strategies for development of telomerase and telomere inhibitors
43. Telomere dysfunction alters the chemotherapeutic profile of transformed cells
44. p53 deficiency rescues the adverse effects of telomerase loss and cooperates with telomere dysfunction to accelerate carcinogenesis
45. Oncogene mutations of the p53 tumor suppressor: The demons of the guardian of the genome